Neurocentria, Inc.
Clinical trials sponsored by Neurocentria, Inc., explained in plain language.
-
ADHD drug trial for teens halted early
Symptom relief TerminatedThis study tested a new drug called NRCT-101SR to see if it could safely reduce ADHD symptoms in teenagers aged 13 to 17. The trial was stopped early, so results are limited. Participants were randomly assigned to receive the drug or a placebo, and researchers tracked symptom cha…
Phase: PHASE2, PHASE3 • Sponsor: Neurocentria, Inc. • Aim: Symptom relief
Last updated May 17, 2026 06:18 UTC
-
ADHD drug combo trial halted after just 2 teens enrolled
Symptom relief TerminatedThis study tested whether adding a new drug (NRCT-101SR) to an existing ADHD medication (NRCT-202XR) could improve symptoms and reduce side effects in teenagers aged 13-17. Only 2 participants were enrolled before the trial was stopped early, so no conclusions can be drawn. The s…
Phase: PHASE2 • Sponsor: Neurocentria, Inc. • Aim: Symptom relief
Last updated May 11, 2026 20:52 UTC